Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Garry A. Neil
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Beta
- 0.79
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.13
Financials
Revenue
$0.00-100.0%Net Income
$-36.36MEBITDA
$-36.32MFree Cash Flow
$-18.08MEPS (diluted)
$-0.83Shares Outstanding (diluted)
43.60M+5875.3%Operating Expenses
$31.52MCash & Debt
$400.28MReturn of Capital
$66.0KRevenue by Segment (annual)
$59.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $59.0K | $-78.26M | $-5.84 |
| 2024 | $441.0K | $-35.13M | $-4.32 |
| 2023 | $1.92M | $-31.54M | $-113.58 |
| 2022 | $18.05M | $-41.66M | $-1062.65 |
| 2021 | $5.40M | $-84.38M | $-2330.66 |
| 2020 | $6.70M | $-63.50M | $-2523.77 |
| 2019 | $6.75M | $-16.07M | $-819.74 |
| 2018 | $18.33M | $-40.05M | $-3317.28 |
| 2017 | $27.81M | $11.87M | $1856.88 |
| 2016 | $1.15M | $-16.47M | $-21.93 |
| 2015 | $0.00 | $-10.49M | $-16.21 |
| 2014 | $0.00 | $-16.06M | $-41.61 |
| 2013 | $0.00 | $-13.05M | $-43.12 |
| 2012 | $82.8K | $-10.49M | $-199.77 |
Valuation
AVTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·7h ago·Neutral
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their upcoming milestones as well. AVTX-010 offers follow-on potential, but its planned IND submission means that it's still years away from becoming a meaningful value driver for AVTX.
View source ↗ - Newsglobenewswire.com·32d ago·Positive
… Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.
View source ↗ - Newsglobenewswire.com·52d ago·Positive
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
View source ↗
Earnings
Thu, Nov 5(in 11 days)
Consensus estimate $-0.59 per share
Typical surprise -31.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.83 vs $-0.58miss
- Wed, May 13$-0.98 vs $-1.00beat
- Mon, Mar 23$-0.74 vs $-1.54beat
- Thu, Nov 6$-2.19 vs $-1.67miss
- Thu, Aug 7$-1.92 vs $-1.43miss
- Mon, May 12$-1.25 vs $-1.07miss
Estimates and results for AVTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AVTX officers and directors.
- Bought
- —
- Sold
- $7.5m
0 trades
33 trades
- Sullivan Christopher Ryansold
- Sullivan Christopher Ryansold
- Doyle Mittiesold
- Sullivan Christopher Ryansold
- Sullivan Christopher Ryansold
- Sullivan Christopher Ryansold
- Doyle Mittiesold
- Riley Jennifersold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AVTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.